Senhwa Biosciences aims at multi-billion dollar global market with CX-5461 combined with ADC “Blockbuster” therapy: Taipei, Taiwan Tuesday, December 30, 2025, 18:00 Hrs [IST] ...
CX-5461 is the first G-quadruplex (G4) stabilizer in development. It has shown promising activity in early-phase trials for breast cancer and other solid tumors in study sponsored by SU2C-CCTG in ...
Clinical Trials Arena on MSN
Senhwa to evaluate Pidnarulex and Enhertu in Phase Ib trial
The combination with Enhertu aims to improve treatment outcomes for HER2-low patients and expand therapeutic options.
Condo sales at the Downtown Brooklyn supertall — the first of its kind outside Manhattan — relaunched this June, a year after ...
The firm is betting that adding the G-quadruplex stabilizer to the ADC will improve outcomes in HER2-low breast cancer patients.
Department of Chemistry, Graduate School of Science, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto 606-8502, Japan, NEC Soft, Ltd., VALWAY Technology ...
State Key Laboratory of Physical Chemistry of the Solid Surfaces, Department of Chemistry, Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen ...
Researchers have identified the specific structural loops in G-quadruplex DNA that allow it to act as a chaperone, preventing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback